Search results
21 paź 2024 · The indications for treatment of pulmonary sarcoidosis can be distilled down to two: significant quality of life and/or functional impairment (more commonly) or a potentially dangerous forms of the disease that may result in severe organ dysfunction, disability, or death .
- Identifying a core outcome set for pulmonary sarcoidosis research – the ...
The FSR-SCOUT study has aimed to address this heterogeneity...
- Pulmonary sarcoidosis: A comprehensive review: Past to present
First line treatment for patients who are symptomatic (cough...
- Identifying a core outcome set for pulmonary sarcoidosis research – the ...
23 wrz 2022 · The FSR-SCOUT study has aimed to address this heterogeneity by developing a core outcome set that represents a patient and health professional consensus on the most important outcomes to measure in future research for the treatment of pulmonary sarcoidosis.
Treatment is directed at alleviating organ dysfunction, preventing irreversible scarring, and improving quality of life. Herein, we review the indications for treatment, pharmacotherapy, treatment duration, side effects, adjunct non-pharmacologic therapies, and outcomes for patients.
The study evaluates the comparative efficacy of non-corticosteroid pharmacological interventions in improving pulmonary outcomes among patients with sarcoidosis. METHODS: We conducted a systematic review and network meta-analysis, identifying randomized controlled trials (RCTs) on pulmonary outcomes in sarcoidosis patients from PubMed, Embase ...
18 lut 2019 · Existing treatment options include either no medication or a mix of first-line, second-line and third-line medication with trade-offs between treating inflammation and quality of life (QoL). 1 A chronic disease course requires long-term treatment with corticosteroids, cytotoxics and other agents that can have a serious impact on the quality of l...
19 gru 2023 · Abstract. Sarcoidosis is a systemic disease with heterogenous clinical phenotypes characterized by non-necrotizing granuloma formation in affected organs. Most disease either remits spontaneously or responds to corticosteroids and second-line disease-modifying therapies.
19 paź 2023 · First line treatment for patients who are symptomatic (cough and dyspnea) with parenchymal infiltrates and abnormal pulmonary function testing (PFT) is oral glucocorticoids, such as prednisone with a typical starting dose of 20-40 mg daily for 2 weeks to 2 months.
